Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

Europe antibiotics market accounted for USD 11.65 billion in 2019 and will grow by 3.4% annually over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 35 tables and 59 figures, this 123-page report Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cephalosporin

Penicillin

Macrolides

Fluoroquinolones

Quinolones

Monobactam

Aminoglycosides

Carbapenem

Other Drug Classes

Based on Action Mechanism, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cell Wall Synthesis Inhibitors

Mycolic Acid Inhibitors

RNA Synthesis Inhibitors

DNA Synthesis Inhibitors

Protein Synthesis Inhibitors

Other Mechanisms

Based on Drug Origin, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Natural Antibiotics

Semi-synthetic Antibiotics

Synthetic Antibiotics

Based on Activity Spectrum, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Broad-spectrum Antibiotics

Narrow-spectrum Antibiotics

Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oral Administration

Intravenous Administration

Other Administration Routes

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Brand Antibiotics

Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Spain

Italy

Russia

Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe antibiotics market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 21

2.2 Major Growth Drivers 23

2.3 Market Restraints and Challenges 27

2.4 Emerging Opportunities and Market Trends 30

2.5 Porter's Fiver Forces Analysis 34

3 Segmentation of Europe Market by Drug Class 38

3.1 Market Overview by Drug Class 38

3.2 Cephalosporin 40

3.3 Penicillin 41

3.4 Macrolides 42

3.5 Fluoroquinolones 43

3.6 Quinolones 44

3.7 Monobactam 45

3.8 Aminoglycosides 46

3.9 Carbapenem 47

3.10 Other Drug Classes 48

4 Segmentation of Europe Market by Action Mechanism 49

4.1 Market Overview by Action Mechanism 49

4.2 Cell Wall Synthesis Inhibitors 51

4.3 Mycolic Acid Inhibitors 52

4.4 RNA Synthesis Inhibitors 53

4.5 DNA Synthesis Inhibitors 54

4.6 Protein Synthesis Inhibitors 55

4.7 Other Mechanisms 56

5 Segmentation of Europe Market by Drug Origin 57

5.1 Market Overview by Drug Origin 57

5.2 Natural Antibiotics 59

5.3 Semi-synthetic Antibiotics 60

5.4 Synthetic Antibiotics 61

6 Segmentation of Europe Market by Activity Spectrum 62

6.1 Market Overview by Activity Spectrum 62

6.2 Broad-spectrum Antibiotics 64

6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of Europe Market by Route of Administration 66

7.1 Market Overview by Route of Administration 66

7.2 Oral Administration 68

7.3 Intravenous Administration 69

7.4 Other Administration Routes 70

8 Segmentation of Europe Market by Drug Type 71

8.1 Market Overview by Drug Type 71

8.2 Brand Antibiotics 73

8.3 Generic Antibiotics 74

9 European Market 2019-2030 by Country 75

9.1 Overview of European Market 75

9.2 Germany 78

9.3 UK 80

9.4 France 83

9.5 Spain 85

9.6 Italy 87

9.7 Russia 89

9.8 Rest of European Market 91

10 Competitive Landscape 93

10.1 Overview of Key Vendors 93

10.2 New Product Launch, Partnership, Investment, and M&A 96

10.3 Company Profiles 97

Abbott Laboratories 97

Astellas Pharma 99

AstraZeneca Plc 100

Bayer AG 101

Bristol Myers Squibb Company 102

Cipla Inc. 103

Dr. Reddy's Laboratories Ltd. 104

Eli Lilly and Company 105

F. Hoffmann-La Roche Ltd. 106

Gilead Sciences, Inc. 107

GlaxoSmithKline plc. 108

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 109

Mayne Pharma Group Ltd. 110

MELINTA THERAPEUTICS, INC. 111

Merck KGaA 112

Novartis AG 113

Pfizer Inc. 114

Sanofi 115

Sun Pharmaceutical Industries Ltd. 116

11 Investing in Europe Market: Risk Assessment and Management 117

11.1 Risk Evaluation of Europe Market 117

11.2 Critical Success Factors (CSFs) 120

Related Reports and Products 123


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. Europe Antibiotics Market, 2019-2030, USD mn 20

Figure 6. Impact of COVID-19 on Business 21

Figure 7. Primary Drivers and Impact Factors of Europe Antibiotics Market 23

Figure 8. GDP per capita in the World, 1960-2018, USD thousand 26

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26

Figure 10. Primary Restraints and Impact Factors of Europe Antibiotics Market 27

Figure 11. Investment Opportunity Analysis 31

Figure 12. Porter's Fiver Forces Analysis of Europe Antibiotics Market 34

Figure 13. Breakdown of Europe Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39

Figure 14. Europe Addressable Market Cap in 2020-2030 by Drug Class, Value (USD mn) and Share (%) 39

Figure 15. Europe Antibiotics Market: Cephalosporin, 2019-2030, USD mn 40

Figure 16. Europe Antibiotics Market: Penicillin, 2019-2030, USD mn 41

Figure 17. Europe Antibiotics Market: Macrolides, 2019-2030, USD mn 42

Figure 18. Europe Antibiotics Market: Fluoroquinolones, 2019-2030, USD mn 43

Figure 19. Europe Antibiotics Market: Quinolones, 2019-2030, USD mn 44

Figure 20. Europe Antibiotics Market: Monobactam, 2019-2030, USD mn 45

Figure 21. Europe Antibiotics Market: Aminoglycosides, 2019-2030, USD mn 46

Figure 22. Europe Antibiotics Market: Carbapenem, 2019-2030, USD mn 47

Figure 23. Europe Antibiotics Market: Other Drug Classes, 2019-2030, USD mn 48

Figure 24. Breakdown of Europe Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50

Figure 25. Europe Addressable Market Cap in 2020-2030 by Action Mechanism, Value (USD mn) and Share (%) 50

Figure 26. Europe Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, USD mn 51

Figure 27. Europe Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, USD mn 52

Figure 28. Europe Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, USD mn 53

Figure 29. Europe Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, USD mn 54

Figure 30. Europe Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, USD mn 55

Figure 31. Europe Antibiotics Market: Other Mechanisms, 2019-2030, USD mn 56

Figure 32. Breakdown of Europe Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58

Figure 33. Europe Addressable Market Cap in 2020-2030 by Drug Origin, Value (USD mn) and Share (%) 58

Figure 34. Europe Antibiotics Market: Natural Antibiotics, 2019-2030, USD mn 59

Figure 35. Europe Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, USD mn 60

Figure 36. Europe Antibiotics Market: Synthetic Antibiotics, 2019-2030, USD mn 61

Figure 37. Breakdown of Europe Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63

Figure 38. Europe Addressable Market Cap in 2020-2030 by Activity Spectrum, Value (USD mn) and Share (%) 63

Figure 39. Europe Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, USD mn 64

Figure 40. Europe Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, USD mn 65

Figure 41. Breakdown of Europe Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67

Figure 42. Europe Addressable Market Cap in 2020-2030 by Route of Administration, Value (USD mn) and Share (%) 67

Figure 43. Europe Antibiotics Market: Oral Administration, 2019-2030, USD mn 68

Figure 44. Europe Antibiotics Market: Intravenous Administration, 2019-2030, USD mn 69

Figure 45. Europe Antibiotics Market: Other Administration Routes, 2019-2030, USD mn 70

Figure 46. Breakdown of Europe Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71

Figure 47. Europe Addressable Market Cap in 2020-2030 by Drug Type, Value (USD bn) and Share (%) 72

Figure 48. Europe Antibiotics Market: Brand Antibiotics, 2019-2030, USD bn 73

Figure 49. Europe Antibiotics Market: Generic Antibiotics, 2019-2030, USD bn 74

Figure 50. Breakdown of European Antibiotics Market by Country, 2019 and 2030, % of Revenue 76

Figure 51. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value (USD bn) and Share (%) 77

Figure 52. Antibiotics Market in Germany, 2019-2030, USD bn 78

Figure 53. Antibiotics Market in UK, 2019-2030, USD bn 80

Figure 54. Antibiotics Market in France, 2019-2030, USD bn 83

Figure 55. Antibiotics Market in Spain, 2019-2030, USD bn 85

Figure 56. Antibiotics Market in Italy, 2019-2030, USD bn 87

Figure 57. Antibiotics Market in Russia, 2019-2030, USD bn 89

Figure 58. Antibiotics Market in Rest of Europe, 2019-2030, USD bn 91

Figure 59. Growth Stage of Europe Antibiotics Industry over the Forecast Period 93


List of Table

Table 1. Snapshot of Europe Antibiotics Market, 2019-2030 18

Table 2. Main Product Trends and Market Opportunities in Europe Antibiotics Market 30

Table 3. Europe Antibiotics Market by Drug Class, 2019-2030, USD mn 38

Table 4. Europe Antibiotics Market by Action Mechanism, 2019-2030, USD mn 49

Table 5. Europe Antibiotics Market by Drug Origin, 2019-2030, USD mn 57

Table 6. Europe Antibiotics Market by Activity Spectrum, 2019-2030, USD mn 62

Table 7. Europe Antibiotics Market by Route of Administration, 2019-2030, USD mn 66

Table 8. Europe Antibiotics Market by Drug Type, 2019-2030, USD bn 71

Table 9. Europe Antibiotics Market by Country, 2019-2030, USD bn 77

Table 10. Germany Antibiotics Market by Drug Class, 2019-2030, USD mn 79

Table 11. Germany Antibiotics Market by Drug Origin, 2019-2030, USD mn 79

Table 12. Germany Antibiotics Market by Route of Administration, 2019-2030, USD mn 79

Table 13. UK Antibiotics Market by Drug Class, 2019-2030, USD mn 82

Table 14. UK Antibiotics Market by Drug Origin, 2019-2030, USD mn 82

Table 15. UK Antibiotics Market by Route of Administration, 2019-2030, USD mn 82

Table 16. France Antibiotics Market by Drug Class, 2019-2030, USD mn 84

Table 17. France Antibiotics Market by Drug Origin, 2019-2030, USD mn 84

Table 18. France Antibiotics Market by Route of Administration, 2019-2030, USD mn 84

Table 19. Spain Antibiotics Market by Drug Class, 2019-2030, USD mn 86

Table 20. Spain Antibiotics Market by Drug Origin, 2019-2030, USD mn 86

Table 21. Spain Antibiotics Market by Route of Administration, 2019-2030, USD mn 86

Table 22. Italy Antibiotics Market by Drug Class, 2019-2030, USD mn 88

Table 23. Italy Antibiotics Market by Drug Origin, 2019-2030, USD mn 88

Table 24. Italy Antibiotics Market by Route of Administration, 2019-2030, USD mn 88

Table 25. Russia Antibiotics Market by Drug Class, 2019-2030, USD mn 90

Table 26. Russia Antibiotics Market by Drug Origin, 2019-2030, USD mn 90

Table 27. Russia Antibiotics Market by Route of Administration, 2019-2030, USD mn 90

Table 28. Antibiotics Market in Rest of Europe by Country, 2019-2030, USD bn 92

Table 29. Abbott Laboratories: Company Snapshot 97

Table 30. Abbott Laboratories: Business Segmentation 97

Table 31. Abbott Laboratories: Product Portfolio 98

Table 32. Abbott Laboratories: Revenue, 2016-2018, USD mn 98

Table 33. Abbott Laboratories: Recent Developments 98

Table 34. Risk Evaluation for Investing in Europe Market, 2019-2030 118

Table 35. Critical Success Factors and Key Takeaways 121

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us

Want the same for your business? Talk To Our Expert